Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Pfizer Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 573 | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 |
| Expenses + | 391 | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 |
| Operating Profit | 182 | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 |
| OPM % | 32% | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% |
| Other Income + | 12 | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 |
| Interest | 3 | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 26 | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 |
| Profit before tax | 165 | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 |
| Tax % | 21% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% |
| Net Profit + | 130 | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 |
| EPS in Rs | 28.34 | 20.44 | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.00 | 43.68 |
Financials of Pfizer Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 |
| Expenses + | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,540 | 1,616 |
| Operating Profit | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 742 | 904 |
| OPM % | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 33% | 36% |
| Other Income + | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 134 | 185 | 344 | 139 |
| Interest | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 8 | 9 |
| Depreciation | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 58 |
| Profit before tax | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 976 |
| Tax % | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% | 26% | 24% | 26% |
| Net Profit + | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 722 |
| EPS in Rs | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 | 120.52 | 167.79 | 157.92 |
| Dividend Payout % | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 29% | 29% | 98% | 48% |
Financials of Pfizer Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 4,157 |
| Borrowings + | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 41 | 70 |
| Other Liabilities + | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 653 | 649 |
| Total Liabilities | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
| Fixed Assets + | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 | 678 |
| CWIP | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 | 20 |
| Investments | 43 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 4,224 |
| Total Assets | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
Financials of Pfizer Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | 660 | 968 |
| Cash from Investing Activity + | 68 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | -71 | -562 |
| Cash from Financing Activity + | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | -205 | -798 |
| Net Cash Flow | 181 | -417 | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 | 383 | -392 |
| Free Cash Flow | 93 | 398 | 394 | 262 | 125 | 343 | 410 | 654 | 292 | 291 | 783 | 944 |
| CFO/OP | 62% | 120% | 146% | 105% | 59% | 93% | 89% | 107% | 81% | 64% | 110% | 105% |
Financials of Pfizer Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 | 31 | 26 |
| Inventory Days | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 | 214 | 195 |
| Days Payable | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 | 68 | 89 |
| Cash Conversion Cycle | 58 | 36 | -10 | -69 | 6 | 31 | 87 | 91 | 107 | 154 | 177 | 132 |
| Working Capital Days | 7 | -9 | -47 | -57 | -16 | -8 | 3 | -14 | 1 | 24 | 23 | 9 |
| ROCE % | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% | 22% | 24% |